APRE — Aprea Therapeutics Share Price
0.000.00%
Last trade - 00:00- $10.22m
- -$11.32m
- $1.50m
- 11
- 34
- 59
- 27
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.53 | ||
| Price to Tang. Book | 0.53 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.8 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -69.45% | ||
| Return on Equity | -71.47% | ||
| Operating Margin | -953% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 0.58 | 1.5 | 0.9 | 0.9 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.
Directors
- Christian Schade CHM (60)
- Scott Coiante CFO (54)
- Lars Abrahmsen SVP (63)
- Eyal Attar SVP (50)
- Gregory Korbel SVP (45)
- John Henneman LED (59)
- Michael Kelly IND (64)
- Fouad Namouni IND (52)
- Richard Peters IND (59)
- Bernd Seizinger IND (65)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 3rd, 2019
- Public Since
- October 3rd, 2019
- No. of Shareholders
- 188
- No. of Employees
- 8
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 5,525,172
- Address
- 3805 OLD EASTON ROAD, DOYLESTOWN, 18902
- Web
- https://www.aprea.com/
- Phone
- +1 2159484119
- Auditors
- EisnerAmper LLP
Upcoming Events for APRE
Aprea Therapeutics Inc Annual Shareholders Meeting
Aprea Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Aprea Therapeutics Inc Earnings Release
Similar to APRE
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Aprea Therapeutics share price?
As of Today at 19:18 UTC, shares in Aprea Therapeutics are trading at $1.85. This share price information is delayed by 15 minutes.
How has the Aprea Therapeutics share price performed this year?
Shares in Aprea Therapeutics last closed at $1.85 and the price had moved by -66.06% over the past 365 days. In terms of relative price strength the Aprea Therapeutics share price has underperformed the S&P500 Index by -69.39% over the past year.
What are the analyst and broker recommendations for Aprea Therapeutics?
The overall consensus recommendation for Aprea Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Aprea Therapeutics dividend yield?
Aprea Therapeutics does not currently pay a dividend.
Does Aprea Therapeutics pay a dividend?
Aprea Therapeutics does not currently pay a dividend.
When does Aprea Therapeutics next pay dividends?
Aprea Therapeutics does not currently pay a dividend.
How do I buy Aprea Therapeutics shares?
To buy shares in Aprea Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Aprea Therapeutics?
As of the previous close price of $1.85, shares in Aprea Therapeutics had a market capitalisation of $10.22m.
Where are Aprea Therapeutics shares listed?
Here are the trading details for Aprea Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: APRE
What kind of share is Aprea Therapeutics?
Based on an overall assessment of its quality, value and momentum Aprea Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Aprea Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Aprea Therapeutics is $10.50. That is 467.6% above the last closing price of $1.85.
Analysts covering Aprea Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.58 for the next financial year.
Find out moreWhat is the trend in the Aprea Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aprea Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -52.59%.
As of the last closing price of $1.85, shares in Aprea Therapeutics were trading -40.57% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Aprea Therapeutics PE Ratio?
The Aprea Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.85.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Aprea Therapeutics?
Aprea Therapeutics' management team is headed by:
- Christian Schade - CHM
- Scott Coiante - CFO
- Lars Abrahmsen - SVP
- Eyal Attar - SVP
- Gregory Korbel - SVP
- John Henneman - LED
- Michael Kelly - IND
- Fouad Namouni - IND
- Richard Peters - IND
- Bernd Seizinger - IND